Success Metrics

Clinical Success Rate
100.0%

Based on 6 completed trials

Completion Rate
100%(6/6)
Active Trials
0(0%)
Results Posted
33%(2 trials)

Phase Distribution

Ph phase_3
2
33%
Ph phase_1
2
33%
Ph phase_2
2
33%

Phase Distribution

2

Early Stage

2

Mid Stage

2

Late Stage

Phase Distribution6 total trials
Phase 1Safety & dosage
2(33.3%)
Phase 2Efficacy & side effects
2(33.3%)
Phase 3Large-scale testing
2(33.3%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

6 of 6 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

6

all time

Status Distribution
Completed(6)

Detailed Status

Completed6

Development Timeline

Analytics

Development Status

Total Trials
6
Active
0
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 12 (33.3%)
Phase 22 (33.3%)
Phase 32 (33.3%)

Trials by Status

completed6100%

Recent Activity

0 active trials
Showing 5 of 6
completedphase_2

Efficacy and Safety of BG00012 in MS

NCT00168701
completedphase_1

A 24-Hour Pharmacokinetic Determination of BG00012 After Single-Day Oral Administration in Subjects With MS

NCT00837785
completedphase_3

Efficacy and Safety Study of Oral BG00012 With Active Reference in Relapsing-Remitting Multiple Sclerosis

NCT00451451
completedphase_3

Efficacy and Safety of Oral BG00012 in Relapsing-Remitting Multiple Sclerosis

NCT00420212
completedphase_2

Efficacy and Safety Study of BG00012 With Methotrexate in Patients With Active Rheumatoid Arthritis

NCT00810836
View all 6 trials

Clinical Trials (6)

Showing 6 of 6 trials
NCT00168701Phase 2

Efficacy and Safety of BG00012 in MS

Completed
NCT00837785Phase 1

A 24-Hour Pharmacokinetic Determination of BG00012 After Single-Day Oral Administration in Subjects With MS

Completed
NCT00451451Phase 3

Efficacy and Safety Study of Oral BG00012 With Active Reference in Relapsing-Remitting Multiple Sclerosis

Completed
NCT00420212Phase 3

Efficacy and Safety of Oral BG00012 in Relapsing-Remitting Multiple Sclerosis

Completed
NCT00810836Phase 2

Efficacy and Safety Study of BG00012 With Methotrexate in Patients With Active Rheumatoid Arthritis

Completed
NCT01069913Phase 1

Pharmacokinetics Profile Study of BG00012 Standard Formulation and BG00012 Active Pharmaceutical Ingredient

Completed

All 6 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
6